14-day Premium Trial Subscription Sign Up For FreeGet Free

Acceleron Pharma Inc. Stock Forecast NASDAQ:XLRN

Price Target and Analyst Ratings

Most Recent Rating

On August 05, 2021 "Piper Sandler" gave "$143.00 - $146.00" rating for XLRN. The price target was set to $127.38+0.7%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-08-05 $143.00 - $146.00 Target Raised by Piper Sandler $127.38 $127.38+0.7%
2021-07-19 $183.00 Initiated by Wolfe Research $118.32 $119.25+1.7%
2021-06-27 Hold Reiterated by SVB Leerink $127.22
2021-06-24 Outperform Target Raised by Oppenheimer $123.93 $141.00 → $160.00
2021-06-15 Hold Reiterated by SVB Leerink $128.71
2021-03-29 Neutral Reiterated by The Goldman Sachs Group $131.46 $132.00
2021-03-29 Outperform - Market Perform Reiterated by SVB Leerink $131.46 $148.00
2021-03-23 Outperform - Market Perform Downgraded by SVB Leerink $135.99 $148.00
2021-03-22 Neutral Reiterated by The Goldman Sachs Group $143.64 $132.00
2021-03-17 Outperform Initiated by Wolfe Research $136.88 $200.00
2021-03-11 Outperform Initiated by Wolfe Research $133.46
2021-03-08 Buy Target Raised by Citigroup $126.21 $137.00 → $171.00
2021-03-04 Outperform Target Raised by SVB Leerink $127.90 $138.00 → $148.00
2021-03-04 Overweight Target Raised by Piper Sandler $127.90 $130.00 → $143.00
2021-03-04 Overweight Target Raised by Morgan Stanley $127.90 $135.00 → $145.00
2021-03-01 Buy Target Raised by Citigroup $140.15 $137.00 → $171.00
2021-02-26 Overweight Target Raised by Piper Sandler $136.16 $130.00 → $143.00
2021-02-26 Overweight Target Raised by Morgan Stanley $136.16 $135.00 → $145.00
2021-02-26 Outperform Target Raised by SVB Leerink $136.16 $138.00 → $148.00
2021-01-29 Overweight Target Raised by JPMorgan Chase & Co. $115.53 $133.00 → $153.00
2021-01-19 Strong-Buy Target Raised by Raymond James $132.47 $155.00 → $160.00
2021-01-19 Buy Target Raised by HC Wainwright $132.47 $148.00 → $168.00
2020-12-21 Overweight Target Raised by Barclays $133.71 $133.00 → $150.00
2020-12-16 Overweight Target Raised by Morgan Stanley $129.03 $130.00 → $135.00
2020-11-16 Outperform Target Raised by Oppenheimer $115.63 $120.00 → $131.00
2020-11-06 Overweight Target Raised by Morgan Stanley $113.44 $125.00 → $130.00
2020-11-06 Buy Target Raised by HC Wainwright $113.44 $137.00 → $148.00
2020-11-06 Outperform Target Raised by SVB Leerink $113.44 $134.00 → $138.00
2020-10-13 Overweight Target Raised by Morgan Stanley $122.18 $123.00 → $125.00
2020-09-29 Buy Reiterated by HC Wainwright $113.11
2020-08-24 Strong-Buy Initiated by Raymond James $89.60
2020-08-07 Outperform Target Raised by SVB Leerink $99.12 $132.00 → $134.00
2020-08-07 Outperform Target Raised by Credit Suisse Group $99.12 $134.00 → $135.00
2020-07-15 Overweight Target Raised by Morgan Stanley $99.20 $122.00 → $123.00
2020-07-07 Overweight Target Lowered by Piper Sandler $102.84 $135.00 → $130.00
2020-06-26 Outperform Target Raised by SVB Leerink $97.86 $127.00 → $132.00
2020-06-25 Outperform Target Raised by Credit Suisse Group $101.93 $123.00 → $134.00
2020-06-25 Buy Reiterated by Oppenheimer $101.93 $115.00 → $120.00
2020-06-25 Sector Perform Target Raised by Royal Bank of Canada $101.93 $72.00 → $99.00
2020-06-25 Outperform Target Raised by Cowen $101.93 $121.00 → $140.00
2020-06-02 Buy Target Raised by Citigroup $96.89 $136.00 → $137.00
2020-05-12 Target Raised by SVB Leerink $100.71 $104.00 → $127.00
2020-05-12 Buy Reiterated by Barclays $100.71 $116.00
2020-05-12 Overweight Target Raised by JPMorgan Chase & Co. $100.71 $108.00 → $118.00
2020-05-12 Outperform Target Raised by Oppenheimer $100.71 $112.00 → $115.00
2020-05-08 Outperform Target Raised by Credit Suisse Group $101.79 $99.00 → $123.00
2020-05-04 Buy Reiterated by HC Wainwright $97.00 $137.00

XLRN Stock Trend

The stock lies in the upper part of a wide and weak rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at $138.16 will firstly indicate a stronger rate of rising.

Given the current short-term trend, the stock is expected to rise 7.73% during the next 3 months and, with a 90% probability hold a price between $131.96 and $148.84 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-20 $122.65 $130.48 $138.31
2021-09-21 $122.81 $130.64 $138.47
2021-09-22 $122.96 $130.80 $138.63
2021-09-23 $123.12 $130.95 $138.79
2021-09-24 $123.28 $131.11 $138.94
2021-09-27 $123.44 $131.27 $139.10
2021-09-28 $123.59 $131.43 $139.26
2021-09-29 $123.75 $131.58 $139.42
2021-09-30 $123.91 $131.74 $139.57
2021-10-01 $124.07 $131.90 $139.73
2021-10-04 $124.22 $132.06 $139.89
2021-10-05 $124.38 $132.21 $140.05
2021-10-06 $124.54 $132.37 $140.20
2021-10-07 $124.70 $132.53 $140.36
2021-10-08 $124.85 $132.69 $140.52
2021-10-11 $125.01 $132.84 $140.68
2021-10-12 $125.17 $133.00 $140.83
2021-10-13 $125.32 $133.16 $140.99
2021-10-14 $125.48 $133.32 $141.15
2021-10-15 $125.64 $133.47 $141.31
2021-10-18 $125.80 $133.63 $141.46
2021-10-19 $125.95 $133.79 $141.62
2021-10-20 $126.11 $133.94 $141.78
2021-10-21 $126.27 $134.10 $141.94
2021-10-22 $126.43 $134.26 $142.09
2021-10-25 $126.58 $134.42 $142.25
2021-10-26 $126.74 $134.57 $142.41
2021-10-27 $126.90 $134.73 $142.56
2021-10-28 $127.06 $134.89 $142.72
2021-10-29 $127.21 $135.05 $142.88

About Acceleron Pharma Inc.

Acceleron Pharma Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. It is developing sotatercept to treat patients with chronic kidney disease, including mineral-bone disorder, vascular calcification, and anemia; and luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassem... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT